Table 4 Cardiovascular control markers in CEA and CAS patients evaluated in PRE, FU6 and FU12 during REST.
REST | CEA | CAS | ||||
---|---|---|---|---|---|---|
PRE | FU6 | FU12 | PRE | FU6 | FU12 | |
µHP [ms] | 932.13 ± 103.76 | 987.74 ± 124.78 | 930.68 ± 138.68 | 851.20 ± 149.97* | 886.93 ± 111.87* | 917.64 ± 130.77 |
σ2HP [ms2] | 701.13 ± 599 | 938.32 ± 759.35 | 668.56 ± 580.04 | 595.97 ± 822.06 | 521.72 ± 610.72* | 559.74 ± 694.53 |
HFHP [ms2] | 147.77 ± 192.81 | 246.57 ± 278.18 | 171.18 ± 349.61 | 143.13 ± 267.38 | 125.74 ± 159.58 | 119.27 ± 140.05 |
LFHP/HFHP | 1.98 ± 2.4 | 1.72 ± 1.99 | 1.57 ± 2.67 | 1.34 ± 1.94 | 1.11 ± 1.93 | 0.82 ± 0.91 |
µSAP [mmHg] | 152.78 ± 28.61 | 143.78 ± 18.78 | 136.87 ± 18.18§ | 148.97 ± 27.43 | 147.47 ± 21.36 | 147.48 ± 24.41 |
σ2SAP [mmHg2] | 27.53 ± 28.76 | 25.94 ± 24.79 | 17.78 ± 10.45 | 24.61 ± 18.41 | 30.53 ± 48.49 | 21.82 ± 12.9 |
LFSAP [mmHg2] | 3.57 ± 8.45 | 5.37 ± 11.76 | 2.83 ± 3.74 | 3.92 ± 4.24 | 2.39 ± 3.4 | 1.89 ± 1.52 |
αLF [ms/mmHg] | 9.43 ± 8.09 | 12.07 ± 16.25 | 7.89 ± 7.34 | 8.27 ± 20.01 | 7.04 ± 7.64 | 6.47 ± 6.7 |
αHF [ms/mmHg] | 6.32 ± 5.56 | 7.96 ± 5.03 | 6.59 ± 3.8 | 5.64 ± 5.8 | 6.35 ± 6.06 | 5.9 ± 5.22 |
K2LF | 0.39 ± 0.21 | 0.43 ± 0.20 | 0.37 ± 0.22 | 0.31 ± 0.2 | 0.37 ± 0.20 | 0.34 ± 0.2 |
PhLF [rad] | -1.15 ± 1.18 | -0.92 ± 1.64 | -1.26 ± 1.39 | -0.62 ± 1.66 | -0.97 ± 1.83 | -0.6 ± 1.74 |
BRSLF [ms/mmHg] | 5.14 ± 4.13 | 8.46 ± 12.04 | 6.42 ± 10.28 | 3.5 ± 3.74 | 4.8 ± 5.03 | 4.77 ± 6.38 |
K2HF | 0.65 ± 0.23 | 0.68 ± 0.21 | 0.64 ± 0.24 | 0.65 ± 0.25 | 0.69 ± 0.24 | 0.67 ± 0.24 |
PhHF [rad] | -0.18 ± 0.67 | 0.33 ± 0.92 | -0.04 ± 0.90 | -0.13 ± 0.84 | -0.27 ± 1.14* | 0.13 ± 1.22 |
BRSHF [ms/mmHg] | 5.94 ± 5.38 | 9.93 ± 18.08 | 6.74 ± 8.49 | 5.36 ± 5.64 | 9.15 ± 15.05 | 6.15 ± 7.5 |